Global Fatty Liver Disease Drugs Market 2026 by Company, Regions, Type and Application, Forecast to 2032

September 2026 | 104 pages | ID: G4C9C64BCC54EN
GlobalInfoResearch

Abstracts

According to our (Global Info Research) latest study, the global Fatty Liver Disease Drugs market size was valued at US$ 1290 million in 2025 and is forecast to a readjusted size of US$ 4405 million by 2032 with a CAGR of 16.8% during review period.

Fatty Liver Disease Drugs are pharmacological products developed to treat steatotic liver diseases characterized by abnormal hepatic fat accumulation, metabolic dysfunction, inflammation and progressive fibrosis. The research scope focuses on approved and investigational therapies for metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), noncirrhotic MASH with moderate-to-advanced fibrosis, compensated MASH cirrhosis, alcohol-associated steatotic liver disease, and fatty liver disease associated with obesity or type 2 diabetes. Major product modalities include small-molecule drugs, peptide and protein therapeutics, RNA-based medicines and combination regimens, delivered primarily through oral tablets or subcutaneous injection. Principal mechanisms include thyroid hormone receptor beta activation, GLP-1 and multi-receptor metabolic agonism, PPAR modulation, FGF21 analog activity, fatty acid synthase inhibition, RNA interference and other metabolic or antifibrotic pathways. The market therefore covers both liver-directed therapies that act on hepatic lipid metabolism and fibrosis and systemic metabolic therapies that improve weight, insulin resistance and associated cardiometabolic risk.

Key Findings

• The average gross profit margin of this product is 35%
• Two targeted MASH therapies are approved across the United States and Europe
• Rezdiffra treated more than 36,250 patients by year-end 2025
• F2–F3 noncirrhotic MASH remains the core commercial treatment population
• Phase III pipelines span PPAR, FGF21 and dual receptor agonists
• Oral and injectable mechanisms are progressing toward combination treatment

Market Trends

The Fatty Liver Disease Drugs market is transitioning from symptom management and control of associated metabolic conditions toward disease-modifying pharmacotherapy supported by histological, imaging and biomarker evidence. The approval of an oral liver-directed thyroid hormone receptor beta agonist established a targeted treatment pathway, while the subsequent approval of injectable semaglutide demonstrated that systemic metabolic intervention can also improve MASH and fibrosis. Development strategies are consequently moving toward a dual approach: reducing hepatic fat, inflammation and fibrosis directly while simultaneously addressing obesity, insulin resistance, dyslipidaemia and cardiovascular risk. Pipeline activity is broadening from single-pathway small molecules to long-acting FGF21 analogs, PPAR agonists, GLP-1/glucagon or other multi-receptor peptides, fatty acid synthase inhibitors and RNA-based therapies. Non-invasive tests are also becoming increasingly important for patient identification, fibrosis staging and treatment monitoring, reducing reliance on liver biopsy in routine clinical pathways. Over the longer term, treatment is likely to become more stratified by fibrosis stage, metabolic phenotype and response profile, with combination regimens used to address the multiple biological drivers of disease progression.

Market Dynamics

Drivers

Growth in Fatty Liver Disease Drugs is primarily supported by the increasing clinical overlap between fatty liver disease, obesity, type 2 diabetes, dyslipidaemia and cardiovascular risk. The availability of the first approved MASH therapies has created a defined pharmaceutical treatment market and is encouraging healthcare systems to establish clearer diagnosis, referral and reimbursement pathways. Improved awareness among hepatologists, endocrinologists and primary-care physicians is expanding the identifiable treatment population, while advances in elastography, blood-based fibrosis tests and imaging-based liver-fat assessment are making high-risk patients easier to detect. Positive regulatory precedents in the United States and Europe also reduce development uncertainty for candidates capable of demonstrating MASH resolution, fibrosis improvement or reduced liver-related clinical events.

Restraints

Commercial expansion remains constrained by underdiagnosis, as early MASLD and MASH frequently progress without specific symptoms and many patients are identified only after substantial fibrosis has developed. Liver biopsy remains an important clinical-trial endpoint but is invasive, costly and unsuitable for broad population screening, while non-invasive diagnostic thresholds are not yet applied uniformly across healthcare systems. Treatment affordability and reimbursement assessment may also limit early uptake, particularly where payers require evidence of advanced fibrosis or specialist confirmation. In addition, approved therapies require continued verification of long-term clinical benefit, and tolerability, drug interactions, treatment duration and adherence can influence real-world adoption. These factors create a substantial gap between the total disease population and the population that is formally diagnosed, eligible and treated.

Opportunities

The most important opportunity lies in expanding treatment beyond noncirrhotic F2–F3 MASH into earlier-stage high-risk disease, compensated MASH cirrhosis and other steatotic liver disorders. Multiple programs are evaluating therapies in advanced fibrosis or cirrhosis, where clinical need remains high and available pharmacological options are limited. Combination treatment represents another major opportunity, particularly regimens pairing a liver-directed antifibrotic agent with a metabolic drug that produces weight loss and glycaemic improvement. Additional potential exists in alcohol-associated steatotic liver disease, obesity- and diabetes-associated fatty liver, and treatment models based on non-invasive patient selection. Markets in which metabolic disease prevalence is high but specialist diagnosis and drug penetration remain relatively low also provide substantial room for future commercial development.

Challenges

Fatty liver disease is biologically heterogeneous, and improvements in liver fat or inflammatory activity do not always translate directly into durable fibrosis regression or fewer clinical events. Developers must therefore conduct long, complex and costly trials that often require histological endpoints followed by confirmatory outcomes studies. Competitive differentiation will become more difficult as therapies with different mechanisms target overlapping F2–F3 populations, requiring evidence not only of efficacy but also of safety, dosing convenience, weight and cardiometabolic benefits, compatibility with combination treatment and sustained real-world adherence. Regulatory standards may continue to evolve as more drugs enter the market, while differences in diagnostic practice and reimbursement policy could produce uneven adoption across regions.

Industry Chain Analysis

The upstream chain for Fatty Liver Disease Drugs includes medicinal chemistry platforms, peptide and protein engineering, RNA synthesis, active pharmaceutical ingredients, excipients, delivery devices, analytical reagents and contract development and manufacturing services. Small-molecule products depend on scalable chemical synthesis and formulation capabilities, while peptide, protein and RNA therapies require more specialized production, purification, cold-chain and quality-control systems. Diagnostic companies and clinical laboratories also play an increasingly important upstream-enabling role by providing fibrosis biomarkers, imaging support and companion patient-selection tools.

The midstream segment covers target discovery, preclinical development, clinical trials, regulatory registration, commercial manufacturing and lifecycle management. The main value is created through intellectual property, differentiated mechanisms, histological and outcomes evidence, manufacturing reliability and access to specialist treatment networks rather than through raw-material inputs alone. Downstream demand is generated by hospitals, hepatology and endocrinology departments, obesity and diabetes clinics, specialty pharmacies and integrated metabolic-care programs. Commercial performance depends on connecting non-invasive screening with specialist confirmation, payer authorization and long-term treatment monitoring, making diagnosis infrastructure and market access integral parts of the pharmaceutical value chain.

Segment Insights

By product modality, the commercial market is currently anchored by oral small-molecule therapy and subcutaneous peptide therapy. Oral thyroid hormone receptor beta agonists provide a liver-directed approach with convenient daily administration, while GLP-1 receptor agonists address MASH through weight reduction and broader metabolic improvement. Within the investigational pipeline, peptide and protein therapies are gaining strategic importance because FGF21 analogs and dual or triple metabolic receptor agonists may influence liver fat, inflammation, fibrosis and systemic metabolic risk simultaneously. Small molecules nevertheless remain important because of their manufacturing scalability, oral dosing potential and suitability for combination regimens.

By mechanism, thyroid hormone receptor beta agonists and GLP-1 receptor agonists represent the first established commercial classes. PPAR agonists, FGF21 analogs and dual incretin or glucagon receptor agonists form the most advanced competitive group behind them, while fatty acid synthase inhibitors, RNA interference therapeutics and other antifibrotic agents provide differentiated development routes. By development status, approved and marketed drugs account for a narrow set of mechanisms, whereas Phase II and Phase III pipelines remain substantially more diverse. This structure indicates that future growth will depend less on expansion of a single drug class and more on clinical differentiation across disease stage, metabolic profile, dosing format and combination potential.

Downstream Market Opportunities

The principal downstream opportunity is the treatment of adults with noncirrhotic MASH and moderate-to-advanced fibrosis, where the first regulatory approvals have established a clinically defined and commercially addressable population. Further demand can emerge from patients with compensated cirrhosis, high-risk MASLD identified through non-invasive testing, and fatty liver associated with obesity or type 2 diabetes. Integrated care involving hepatology, endocrinology, cardiology and weight-management services is particularly relevant because many eligible patients have multiple metabolic comorbidities. Alcohol-associated steatotic liver disease may become an additional development area as therapies capable of reducing inflammation and fibrosis are evaluated across broader liver-disease populations. The largest downstream value will be created by treatment pathways that identify patients earlier, match therapy to fibrosis and metabolic risk, and maintain long-term adherence.

Regional Insights

North America is currently the most developed commercial region for Fatty Liver Disease Drugs. The United States established the first dedicated MASH approval in March 2024, followed by approval of semaglutide for MASH in August 2025. Early prescribing experience, specialist liver networks and the expansion of payer coverage have given the region a leading position in treated-patient volume and commercial adoption. By year-end 2025, Madrigal reported that more than 36,250 patients were receiving Rezdiffra, illustrating the speed with which a previously untreated pharmaceutical category began to form.

Europe entered a broader commercialization phase after conditional authorizations for Rezdiffra in August 2025 and Kayshild in March 2026. Uptake is expected to vary by country because health-technology assessment, specialist referral pathways and reimbursement decisions remain decentralized. Asia-Pacific represents a significant long-term expansion opportunity, supported by the development of regional PPAR, FGF21, fatty acid synthase and metabolic agonist programs. China and India have active domestic development or commercialization platforms, but differences in diagnosis rates, regulatory status, affordability and reimbursement will continue to shape market access.

Report Scope

This report is a detailed and comprehensive analysis for global Fatty Liver Disease Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Fatty Liver Disease Drugs market size and forecasts, in consumption value ($ Million), 2021-2032

Global Fatty Liver Disease Drugs market size and forecasts by region and country, in consumption value ($ Million), 2021-2032

Global Fatty Liver Disease Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032

Global Fatty Liver Disease Drugs market shares of main players, in revenue ($ Million), 2021-2026

The Primary Objectives in This Report Are:

• To determine the size of the total market opportunity of global and key countries
• To assess the growth potential for Fatty Liver Disease Drugs
• To forecast future growth in each product and end-use market
• To assess competitive factors affecting the marketplace

This report profiles key players in the global Fatty Liver Disease Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Madrigal Pharmaceuticals, Novo Nordisk, Zydus Lifescience, Inventiva, Chia Tai Tianqing Pharmaceutical, Boehringer Ingelheim, Zealand Pharma, Roche, GSK, Eli Lilly, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Fatty Liver Disease Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation

Market segment by Type

• Small-Molecule Drugs
• Peptide and Protein Drugs
• RNA-Based Therapeutics
• Other

Market segment by Route of Administration

• Oral Drugs
• Subcutaneous Injectable Drugs
• Other Injectable Drugs

Market segment by Disease

• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
• Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• MASH with Moderate-to-Advanced Fibrosis
• Compensated MASH Cirrhosis
• Other

Market segment by Application

• Hospitals
• Retail Pharmacies
• Others

Market segment by players, this report covers

• Madrigal Pharmaceuticals
• Novo Nordisk
• Zydus Lifescience
• Inventiva
• Chia Tai Tianqing Pharmaceutical
• Boehringer Ingelheim
• Zealand Pharma
• Roche
• GSK
• Eli Lilly
• Viking Therapeutics
• Alnylam Pharmaceutical
• Regeneron Pharmaceuticals
• Sagimet Biosciences

Market segment by regions, regional analysis covers

• North America (United States, Canada and Mexico)
• Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
• South America (Brazil, Rest of South America)
• Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

Chapter Outline

Chapter 1, to describe Fatty Liver Disease Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Fatty Liver Disease Drugs, with revenue, gross margin, and global market share of Fatty Liver Disease Drugs from 2021 to 2026.
Chapter 3, the Fatty Liver Disease Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Fatty Liver Disease Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Fatty Liver Disease Drugs.
Chapter 13, to describe Fatty Liver Disease Drugs research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Fatty Liver Disease Drugs by Type
  1.3.1 Overview: Global Fatty Liver Disease Drugs Market Size by Type: 2021 Versus 2025 Versus 2032
  1.3.2 Global Fatty Liver Disease Drugs Consumption Value Market Share by Type in 2025
  1.3.3 Small-Molecule Drugs
  1.3.4 Peptide and Protein Drugs
  1.3.5 RNA-Based Therapeutics
  1.3.6 Other
1.4 Classification of Fatty Liver Disease Drugs by Route of Administration
  1.4.1 Overview: Global Fatty Liver Disease Drugs Market Size by Route of Administration: 2021 Versus 2025 Versus 2032
  1.4.2 Global Fatty Liver Disease Drugs Consumption Value Market Share by Route of Administration in 2025
  1.4.3 Oral Drugs
  1.4.4 Subcutaneous Injectable Drugs
  1.4.5 Other Injectable Drugs
1.5 Classification of Fatty Liver Disease Drugs by Disease
  1.5.1 Overview: Global Fatty Liver Disease Drugs Market Size by Disease: 2021 Versus 2025 Versus 2032
  1.5.2 Global Fatty Liver Disease Drugs Consumption Value Market Share by Disease in 2025
  1.5.3 Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  1.5.4 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
  1.5.5 MASH with Moderate-to-Advanced Fibrosis
  1.5.6 Compensated MASH Cirrhosis
  1.5.7 Other
1.6 Global Fatty Liver Disease Drugs Market by Application
  1.6.1 Overview: Global Fatty Liver Disease Drugs Market Size by Application: 2021 Versus 2025 Versus 2032
  1.6.2 Hospitals
  1.6.3 Retail Pharmacies
  1.6.4 Others
1.7 Global Fatty Liver Disease Drugs Market Size & Forecast
1.8 Global Fatty Liver Disease Drugs Market Size and Forecast by Region
  1.8.1 Global Fatty Liver Disease Drugs Market Size by Region: 2021 VS 2025 VS 2032
  1.8.2 Global Fatty Liver Disease Drugs Market Size by Region, (2021-2032)
  1.8.3 North America Fatty Liver Disease Drugs Market Size and Prospect (2021-2032)
  1.8.4 Europe Fatty Liver Disease Drugs Market Size and Prospect (2021-2032)
  1.8.5 Asia-Pacific Fatty Liver Disease Drugs Market Size and Prospect (2021-2032)
  1.8.6 South America Fatty Liver Disease Drugs Market Size and Prospect (2021-2032)
  1.8.7 Middle East & Africa Fatty Liver Disease Drugs Market Size and Prospect (2021-2032)

2 COMPANY PROFILES

2.1 Madrigal Pharmaceuticals
  2.1.1 Madrigal Pharmaceuticals Details
  2.1.2 Madrigal Pharmaceuticals Major Business
  2.1.3 Madrigal Pharmaceuticals Fatty Liver Disease Drugs Product and Solutions
  2.1.4 Madrigal Pharmaceuticals Fatty Liver Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
  2.1.5 Madrigal Pharmaceuticals Recent Developments and Future Plans
2.2 Novo Nordisk
  2.2.1 Novo Nordisk Details
  2.2.2 Novo Nordisk Major Business
  2.2.3 Novo Nordisk Fatty Liver Disease Drugs Product and Solutions
  2.2.4 Novo Nordisk Fatty Liver Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
  2.2.5 Novo Nordisk Recent Developments and Future Plans
2.3 Zydus Lifescience
  2.3.1 Zydus Lifescience Details
  2.3.2 Zydus Lifescience Major Business
  2.3.3 Zydus Lifescience Fatty Liver Disease Drugs Product and Solutions
  2.3.4 Zydus Lifescience Fatty Liver Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
  2.3.5 Zydus Lifescience Recent Developments and Future Plans
2.4 Inventiva
  2.4.1 Inventiva Details
  2.4.2 Inventiva Major Business
  2.4.3 Inventiva Fatty Liver Disease Drugs Product and Solutions
  2.4.4 Inventiva Fatty Liver Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
  2.4.5 Inventiva Recent Developments and Future Plans
2.5 Chia Tai Tianqing Pharmaceutical
  2.5.1 Chia Tai Tianqing Pharmaceutical Details
  2.5.2 Chia Tai Tianqing Pharmaceutical Major Business
  2.5.3 Chia Tai Tianqing Pharmaceutical Fatty Liver Disease Drugs Product and Solutions
  2.5.4 Chia Tai Tianqing Pharmaceutical Fatty Liver Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
  2.5.5 Chia Tai Tianqing Pharmaceutical Recent Developments and Future Plans
2.6 Boehringer Ingelheim
  2.6.1 Boehringer Ingelheim Details
  2.6.2 Boehringer Ingelheim Major Business
  2.6.3 Boehringer Ingelheim Fatty Liver Disease Drugs Product and Solutions
  2.6.4 Boehringer Ingelheim Fatty Liver Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
  2.6.5 Boehringer Ingelheim Recent Developments and Future Plans
2.7 Zealand Pharma
  2.7.1 Zealand Pharma Details
  2.7.2 Zealand Pharma Major Business
  2.7.3 Zealand Pharma Fatty Liver Disease Drugs Product and Solutions
  2.7.4 Zealand Pharma Fatty Liver Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
  2.7.5 Zealand Pharma Recent Developments and Future Plans
2.8 Roche
  2.8.1 Roche Details
  2.8.2 Roche Major Business
  2.8.3 Roche Fatty Liver Disease Drugs Product and Solutions
  2.8.4 Roche Fatty Liver Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
  2.8.5 Roche Recent Developments and Future Plans
2.9 GSK
  2.9.1 GSK Details
  2.9.2 GSK Major Business
  2.9.3 GSK Fatty Liver Disease Drugs Product and Solutions
  2.9.4 GSK Fatty Liver Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
  2.9.5 GSK Recent Developments and Future Plans
2.10 Eli Lilly
  2.10.1 Eli Lilly Details
  2.10.2 Eli Lilly Major Business
  2.10.3 Eli Lilly Fatty Liver Disease Drugs Product and Solutions
  2.10.4 Eli Lilly Fatty Liver Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
  2.10.5 Eli Lilly Recent Developments and Future Plans
2.11 Viking Therapeutics
  2.11.1 Viking Therapeutics Details
  2.11.2 Viking Therapeutics Major Business
  2.11.3 Viking Therapeutics Fatty Liver Disease Drugs Product and Solutions
  2.11.4 Viking Therapeutics Fatty Liver Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
  2.11.5 Viking Therapeutics Recent Developments and Future Plans
2.12 Alnylam Pharmaceutical
  2.12.1 Alnylam Pharmaceutical Details
  2.12.2 Alnylam Pharmaceutical Major Business
  2.12.3 Alnylam Pharmaceutical Fatty Liver Disease Drugs Product and Solutions
  2.12.4 Alnylam Pharmaceutical Fatty Liver Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
  2.12.5 Alnylam Pharmaceutical Recent Developments and Future Plans
2.13 Regeneron Pharmaceuticals
  2.13.1 Regeneron Pharmaceuticals Details
  2.13.2 Regeneron Pharmaceuticals Major Business
  2.13.3 Regeneron Pharmaceuticals Fatty Liver Disease Drugs Product and Solutions
  2.13.4 Regeneron Pharmaceuticals Fatty Liver Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
  2.13.5 Regeneron Pharmaceuticals Recent Developments and Future Plans
2.14 Sagimet Biosciences
  2.14.1 Sagimet Biosciences Details
  2.14.2 Sagimet Biosciences Major Business
  2.14.3 Sagimet Biosciences Fatty Liver Disease Drugs Product and Solutions
  2.14.4 Sagimet Biosciences Fatty Liver Disease Drugs Revenue, Gross Margin and Market Share (2021-2026)
  2.14.5 Sagimet Biosciences Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Fatty Liver Disease Drugs Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
  3.2.1 Market Share of Fatty Liver Disease Drugs by Company Revenue
  3.2.2 Top 3 Fatty Liver Disease Drugs Players Market Share in 2025
  3.2.3 Top 6 Fatty Liver Disease Drugs Players Market Share in 2025
3.3 Fatty Liver Disease Drugs Market: Overall Company Footprint Analysis
  3.3.1 Fatty Liver Disease Drugs Market: Region Footprint
  3.3.2 Fatty Liver Disease Drugs Market: Company Product Type Footprint
  3.3.3 Fatty Liver Disease Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Fatty Liver Disease Drugs Consumption Value and Market Share by Type (2021-2026)
4.2 Global Fatty Liver Disease Drugs Market Forecast by Type (2027-2032)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Fatty Liver Disease Drugs Consumption Value Market Share by Application (2021-2026)
5.2 Global Fatty Liver Disease Drugs Market Forecast by Application (2027-2032)

6 NORTH AMERICA

6.1 North America Fatty Liver Disease Drugs Consumption Value by Type (2021-2032)
6.2 North America Fatty Liver Disease Drugs Market Size by Application (2021-2032)
6.3 North America Fatty Liver Disease Drugs Market Size by Country
  6.3.1 North America Fatty Liver Disease Drugs Consumption Value by Country (2021-2032)
  6.3.2 United States Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)
  6.3.3 Canada Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)
  6.3.4 Mexico Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)

7 EUROPE

7.1 Europe Fatty Liver Disease Drugs Consumption Value by Type (2021-2032)
7.2 Europe Fatty Liver Disease Drugs Consumption Value by Application (2021-2032)
7.3 Europe Fatty Liver Disease Drugs Market Size by Country
  7.3.1 Europe Fatty Liver Disease Drugs Consumption Value by Country (2021-2032)
  7.3.2 Germany Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)
  7.3.3 France Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)
  7.3.4 United Kingdom Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)
  7.3.5 Russia Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)
  7.3.6 Italy Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)

8 ASIA-PACIFIC

8.1 Asia-Pacific Fatty Liver Disease Drugs Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Fatty Liver Disease Drugs Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Fatty Liver Disease Drugs Market Size by Region
  8.3.1 Asia-Pacific Fatty Liver Disease Drugs Consumption Value by Region (2021-2032)
  8.3.2 China Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)
  8.3.3 Japan Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)
  8.3.4 South Korea Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)
  8.3.5 India Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)
  8.3.6 Southeast Asia Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)
  8.3.7 Australia Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)

9 SOUTH AMERICA

9.1 South America Fatty Liver Disease Drugs Consumption Value by Type (2021-2032)
9.2 South America Fatty Liver Disease Drugs Consumption Value by Application (2021-2032)
9.3 South America Fatty Liver Disease Drugs Market Size by Country
  9.3.1 South America Fatty Liver Disease Drugs Consumption Value by Country (2021-2032)
  9.3.2 Brazil Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)
  9.3.3 Argentina Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Fatty Liver Disease Drugs Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Fatty Liver Disease Drugs Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Fatty Liver Disease Drugs Market Size by Country
  10.3.1 Middle East & Africa Fatty Liver Disease Drugs Consumption Value by Country (2021-2032)
  10.3.2 Turkey Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)
  10.3.3 Saudi Arabia Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)
  10.3.4 UAE Fatty Liver Disease Drugs Market Size and Forecast (2021-2032)

11 MARKET DYNAMICS

11.1 Fatty Liver Disease Drugs Market Drivers
11.2 Fatty Liver Disease Drugs Market Restraints
11.3 Fatty Liver Disease Drugs Trends Analysis
11.4 Porters Five Forces Analysis
  11.4.1 Threat of New Entrants
  11.4.2 Bargaining Power of Suppliers
  11.4.3 Bargaining Power of Buyers
  11.4.4 Threat of Substitutes
  11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

12.1 Fatty Liver Disease Drugs Industry Chain
12.2 Fatty Liver Disease Drugs Upstream Analysis
12.3 Fatty Liver Disease Drugs Midstream Analysis
12.4 Fatty Liver Disease Drugs Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Fatty Liver Disease Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Fatty Liver Disease Drugs Consumption Value by Route of Administration, (USD Million), 2021 & 2025 & 2032
Table 3. Global Fatty Liver Disease Drugs Consumption Value by Disease, (USD Million), 2021 & 2025 & 2032
Table 4. Global Fatty Liver Disease Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Fatty Liver Disease Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Fatty Liver Disease Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Madrigal Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 8. Madrigal Pharmaceuticals Major Business
Table 9. Madrigal Pharmaceuticals Fatty Liver Disease Drugs Product and Solutions
Table 10. Madrigal Pharmaceuticals Fatty Liver Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Madrigal Pharmaceuticals Recent Developments and Future Plans
Table 12. Novo Nordisk Company Information, Head Office, and Major Competitors
Table 13. Novo Nordisk Major Business
Table 14. Novo Nordisk Fatty Liver Disease Drugs Product and Solutions
Table 15. Novo Nordisk Fatty Liver Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Novo Nordisk Recent Developments and Future Plans
Table 17. Zydus Lifescience Company Information, Head Office, and Major Competitors
Table 18. Zydus Lifescience Major Business
Table 19. Zydus Lifescience Fatty Liver Disease Drugs Product and Solutions
Table 20. Zydus Lifescience Fatty Liver Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Inventiva Company Information, Head Office, and Major Competitors
Table 22. Inventiva Major Business
Table 23. Inventiva Fatty Liver Disease Drugs Product and Solutions
Table 24. Inventiva Fatty Liver Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Inventiva Recent Developments and Future Plans
Table 26. Chia Tai Tianqing Pharmaceutical Company Information, Head Office, and Major Competitors
Table 27. Chia Tai Tianqing Pharmaceutical Major Business
Table 28. Chia Tai Tianqing Pharmaceutical Fatty Liver Disease Drugs Product and Solutions
Table 29. Chia Tai Tianqing Pharmaceutical Fatty Liver Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Chia Tai Tianqing Pharmaceutical Recent Developments and Future Plans
Table 31. Boehringer Ingelheim Company Information, Head Office, and Major Competitors
Table 32. Boehringer Ingelheim Major Business
Table 33. Boehringer Ingelheim Fatty Liver Disease Drugs Product and Solutions
Table 34. Boehringer Ingelheim Fatty Liver Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Boehringer Ingelheim Recent Developments and Future Plans
Table 36. Zealand Pharma Company Information, Head Office, and Major Competitors
Table 37. Zealand Pharma Major Business
Table 38. Zealand Pharma Fatty Liver Disease Drugs Product and Solutions
Table 39. Zealand Pharma Fatty Liver Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Zealand Pharma Recent Developments and Future Plans
Table 41. Roche Company Information, Head Office, and Major Competitors
Table 42. Roche Major Business
Table 43. Roche Fatty Liver Disease Drugs Product and Solutions
Table 44. Roche Fatty Liver Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Roche Recent Developments and Future Plans
Table 46. GSK Company Information, Head Office, and Major Competitors
Table 47. GSK Major Business
Table 48. GSK Fatty Liver Disease Drugs Product and Solutions
Table 49. GSK Fatty Liver Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. GSK Recent Developments and Future Plans
Table 51. Eli Lilly Company Information, Head Office, and Major Competitors
Table 52. Eli Lilly Major Business
Table 53. Eli Lilly Fatty Liver Disease Drugs Product and Solutions
Table 54. Eli Lilly Fatty Liver Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Eli Lilly Recent Developments and Future Plans
Table 56. Viking Therapeutics Company Information, Head Office, and Major Competitors
Table 57. Viking Therapeutics Major Business
Table 58. Viking Therapeutics Fatty Liver Disease Drugs Product and Solutions
Table 59. Viking Therapeutics Fatty Liver Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Viking Therapeutics Recent Developments and Future Plans
Table 61. Alnylam Pharmaceutical Company Information, Head Office, and Major Competitors
Table 62. Alnylam Pharmaceutical Major Business
Table 63. Alnylam Pharmaceutical Fatty Liver Disease Drugs Product and Solutions
Table 64. Alnylam Pharmaceutical Fatty Liver Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Alnylam Pharmaceutical Recent Developments and Future Plans
Table 66. Regeneron Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 67. Regeneron Pharmaceuticals Major Business
Table 68. Regeneron Pharmaceuticals Fatty Liver Disease Drugs Product and Solutions
Table 69. Regeneron Pharmaceuticals Fatty Liver Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Regeneron Pharmaceuticals Recent Developments and Future Plans
Table 71. Sagimet Biosciences Company Information, Head Office, and Major Competitors
Table 72. Sagimet Biosciences Major Business
Table 73. Sagimet Biosciences Fatty Liver Disease Drugs Product and Solutions
Table 74. Sagimet Biosciences Fatty Liver Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. Sagimet Biosciences Recent Developments and Future Plans
Table 76. Global Fatty Liver Disease Drugs Revenue (USD Million) by Players (2021-2026)
Table 77. Global Fatty Liver Disease Drugs Revenue Share by Players (2021-2026)
Table 78. Breakdown of Fatty Liver Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 79. Market Position of Players in Fatty Liver Disease Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 80. Head Office of Key Fatty Liver Disease Drugs Players
Table 81. Fatty Liver Disease Drugs Market: Company Product Type Footprint
Table 82. Fatty Liver Disease Drugs Market: Company Product Application Footprint
Table 83. Fatty Liver Disease Drugs New Market Entrants and Barriers to Market Entry
Table 84. Fatty Liver Disease Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 85. Global Fatty Liver Disease Drugs Consumption Value (USD Million) by Type (2021-2026)
Table 86. Global Fatty Liver Disease Drugs Consumption Value Share by Type (2021-2026)
Table 87. Global Fatty Liver Disease Drugs Consumption Value Forecast by Type (2027-2032)
Table 88. Global Fatty Liver Disease Drugs Consumption Value by Application (2021-2026)
Table 89. Global Fatty Liver Disease Drugs Consumption Value Forecast by Application (2027-2032)
Table 90. North America Fatty Liver Disease Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 91. North America Fatty Liver Disease Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 92. North America Fatty Liver Disease Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 93. North America Fatty Liver Disease Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 94. North America Fatty Liver Disease Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 95. North America Fatty Liver Disease Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 96. Europe Fatty Liver Disease Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 97. Europe Fatty Liver Disease Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 98. Europe Fatty Liver Disease Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 99. Europe Fatty Liver Disease Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 100. Europe Fatty Liver Disease Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 101. Europe Fatty Liver Disease Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 102. Asia-Pacific Fatty Liver Disease Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 103. Asia-Pacific Fatty Liver Disease Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 104. Asia-Pacific Fatty Liver Disease Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 105. Asia-Pacific Fatty Liver Disease Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 106. Asia-Pacific Fatty Liver Disease Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 107. Asia-Pacific Fatty Liver Disease Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 108. South America Fatty Liver Disease Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 109. South America Fatty Liver Disease Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 110. South America Fatty Liver Disease Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 111. South America Fatty Liver Disease Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 112. South America Fatty Liver Disease Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 113. South America Fatty Liver Disease Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 114. Middle East & Africa Fatty Liver Disease Drugs Consumption Value by Type (2021-2026) & (USD Million)
Table 115. Middle East & Africa Fatty Liver Disease Drugs Consumption Value by Type (2027-2032) & (USD Million)
Table 116. Middle East & Africa Fatty Liver Disease Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 117. Middle East & Africa Fatty Liver Disease Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 118. Middle East & Africa Fatty Liver Disease Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 119. Middle East & Africa Fatty Liver Disease Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 120. Global Key Players of Fatty Liver Disease Drugs Upstream (Raw Materials)
Table 121. Global Fatty Liver Disease Drugs Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Fatty Liver Disease Drugs Picture
Figure 2. Global Fatty Liver Disease Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Fatty Liver Disease Drugs Consumption Value Market Share by Type in 2025
Figure 4. Small-Molecule Drugs
Figure 5. Peptide and Protein Drugs
Figure 6. RNA-Based Therapeutics
Figure 7. Other
Figure 8. Global Fatty Liver Disease Drugs Consumption Value by Route of Administration, (USD Million), 2021 & 2025 & 2032
Figure 9. Global Fatty Liver Disease Drugs Consumption Value Market Share by Route of Administration in 2025
Figure 10. Oral Drugs
Figure 11. Subcutaneous Injectable Drugs
Figure 12. Other Injectable Drugs
Figure 13. Global Fatty Liver Disease Drugs Consumption Value by Disease, (USD Million), 2021 & 2025 & 2032
Figure 14. Global Fatty Liver Disease Drugs Consumption Value Market Share by Disease in 2025
Figure 15. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Figure 16. Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Figure 17. MASH with Moderate-to-Advanced Fibrosis
Figure 18. Compensated MASH Cirrhosis
Figure 19. Other
Figure 20. Global Fatty Liver Disease Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 21. Fatty Liver Disease Drugs Consumption Value Market Share by Application in 2025
Figure 22. Hospitals Picture
Figure 23. Retail Pharmacies Picture
Figure 24. Others Picture
Figure 25. Global Fatty Liver Disease Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 26. Global Fatty Liver Disease Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 27. Global Market Fatty Liver Disease Drugs Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 28. Global Fatty Liver Disease Drugs Consumption Value Market Share by Region (2021-2032)
Figure 29. Global Fatty Liver Disease Drugs Consumption Value Market Share by Region in 2025
Figure 30. North America Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 31. Europe Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 32. Asia-Pacific Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 33. South America Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 34. Middle East & Africa Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 35. Company Three Recent Developments and Future Plans
Figure 36. Global Fatty Liver Disease Drugs Revenue Share by Players in 2025
Figure 37. Fatty Liver Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 38. Market Share of Fatty Liver Disease Drugs by Player Revenue in 2025
Figure 39. Top 3 Fatty Liver Disease Drugs Players Market Share in 2025
Figure 40. Top 6 Fatty Liver Disease Drugs Players Market Share in 2025
Figure 41. Global Fatty Liver Disease Drugs Consumption Value Share by Type (2021-2026)
Figure 42. Global Fatty Liver Disease Drugs Market Share Forecast by Type (2027-2032)
Figure 43. Global Fatty Liver Disease Drugs Consumption Value Share by Application (2021-2026)
Figure 44. Global Fatty Liver Disease Drugs Market Share Forecast by Application (2027-2032)
Figure 45. North America Fatty Liver Disease Drugs Consumption Value Market Share by Type (2021-2032)
Figure 46. North America Fatty Liver Disease Drugs Consumption Value Market Share by Application (2021-2032)
Figure 47. North America Fatty Liver Disease Drugs Consumption Value Market Share by Country (2021-2032)
Figure 48. United States Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 49. Canada Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 50. Mexico Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 51. Europe Fatty Liver Disease Drugs Consumption Value Market Share by Type (2021-2032)
Figure 52. Europe Fatty Liver Disease Drugs Consumption Value Market Share by Application (2021-2032)
Figure 53. Europe Fatty Liver Disease Drugs Consumption Value Market Share by Country (2021-2032)
Figure 54. Germany Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 55. France Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 56. United Kingdom Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 57. Russia Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 58. Italy Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 59. Asia-Pacific Fatty Liver Disease Drugs Consumption Value Market Share by Type (2021-2032)
Figure 60. Asia-Pacific Fatty Liver Disease Drugs Consumption Value Market Share by Application (2021-2032)
Figure 61. Asia-Pacific Fatty Liver Disease Drugs Consumption Value Market Share by Region (2021-2032)
Figure 62. China Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 63. Japan Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 64. South Korea Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 65. India Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 66. Southeast Asia Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 67. Australia Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 68. South America Fatty Liver Disease Drugs Consumption Value Market Share by Type (2021-2032)
Figure 69. South America Fatty Liver Disease Drugs Consumption Value Market Share by Application (2021-2032)
Figure 70. South America Fatty Liver Disease Drugs Consumption Value Market Share by Country (2021-2032)
Figure 71. Brazil Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 72. Argentina Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 73. Middle East & Africa Fatty Liver Disease Drugs Consumption Value Market Share by Type (2021-2032)
Figure 74. Middle East & Africa Fatty Liver Disease Drugs Consumption Value Market Share by Application (2021-2032)
Figure 75. Middle East & Africa Fatty Liver Disease Drugs Consumption Value Market Share by Country (2021-2032)
Figure 76. Turkey Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 77. Saudi Arabia Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 78. UAE Fatty Liver Disease Drugs Consumption Value (2021-2032) & (USD Million)
Figure 79. Fatty Liver Disease Drugs Market Drivers
Figure 80. Fatty Liver Disease Drugs Market Restraints
Figure 81. Fatty Liver Disease Drugs Market Trends
Figure 82. Porters Five Forces Analysis
Figure 83. Fatty Liver Disease Drugs Industrial Chain
Figure 84. Methodology
Figure 85. Research Process and Data Source